Demographics of the enrolled population
| Protocol population | |
| Subjects n | 105 |
| Male sex | 70 (67) |
| Age years | 12.4 (5.4–17.3) |
| STRA | 24 (23) |
| DA | 52 (50) |
| Mild/moderate asthma | 29 (28) |
| Weight kg | 45 (17–101) |
| Weight centiles | 62 (1–100) |
| Height cm | 149 (108–184) |
| Height centiles | 37 (0–99) |
| Gestational age: | |
| Term born (>37 weeks) | 91 (87) |
| Preterm (30–37weeks) | 13 (12) |
| Severe preterm (<30 weeks) | 1 (1) |
| Comorbidity | 19 (18) |
| Gastro-oesophageal reflux | 23 (22) |
| Median age of symptom onset months | 12 (1–132) |
| Atopy | 92 (88) |
| Family history of atopy | 88 (84) |
| Parental smoking | 19 (18) |
| Hospitalisation due to asthma in the last year | 38 (36) |
| Treatment | |
| Rescue medication | 105 (100) |
| Leukotriene-receptor-antagonist | 61 (58) |
| Long-acting β-agonist | 100 (95) |
| Theophylline | 10 (10) |
| Maintenance OCS | 8 (8) |
| Omalizumab | 4 (4) |
| Immunosuppressants (methotrexate) | 2 (2) |
| Median ICS dose μg BDP per day | 800 (0–3200) |
| Median FeNO value ppb | 35 (5–196) |
| FVC % pred | 95.3±16.37 |
| FEV1 % pred | 86.1±18.73 |
| Median FEF25–75% % pred | 61 (16–189) |
| Median BDR % | 8.4 (0–123) |
Data are presented as n (%), median (range) or mean±sd. STRA: severe therapy-resistant asthma; DA: difficult asthma; BMI: body mass index; ICS: inhaled corticosteroids; BDP: budesonide propionate; OCS: oral corticosteroids; FeNO: fractional exhaled nitric oxide; FVC: forced vital capacity; % pred: % predicted; FEF25–75%: forced expiratory flow at 25–75% of FVC; FEV1: forced expiratory volume in 1 s; BDR: bronchodilator reversibility in %.